This international multicenter cohort study (8 centers across Austria, Italy, Germany, and the Netherlands; January 2016–February 2026) derived and validated disease-specific echocardiographic TR severity thresholds in 1,124 newly diagnosed ATTR-CM patients, comparing their prognostic performance for all-cause mortality and heart failure hospitalization (HFH) against current ESC/EACTS, AHA/ACC, ASE, and TVARC grading schemes.
Spline-derived thresholds classified 29.7% of patients (n=334) as high or extreme risk, versus only 11.6% (n=130) with guideline-defined severe TR (P<0.001). The new framework carried the highest adjusted hazard ratios for mortality (HR 1.41; 95% CI 1.23–1.62) and HFH (HR 1.31; 95% CI 1.12–1.54), with extreme-risk patients showing 4- to 6-fold higher mortality vs. low-risk. Time-dependent AUC was consistently superior to ESC/EACTS–AHA/ACC at all time points; in the non-amyloid HF cohort (n=364), the framework offered no discriminatory advantage.
- Derivation and validation cohorts differed in several baseline characteristics (e.g., ATTR subtype distribution, ATTR-specific therapy use, SGLT-2i use), which may limit generalizability. - Missing quantitative TR data required median imputation by local TR grade, though a complete-case sensitivity analysis was performed. - The atrial functional TR subgroup was defined by a pragmatic proxy (right atrial dilatation + normal RV size) rather than a validated dedicated algorithm.
Standard guideline TR grading misses nearly two-thirds of ATTR-CM patients who carry significant prognostic risk; clinicians should consider applying quantitative thresholds (VCW ≥3 mm, EROA ≥0.15 cm², RegVol ≥10 mL for intermediate risk) specific to ATTR-CM's restrictive low-flow physiology. These disease-specific cut-offs should not be applied to non-amyloid heart failure populations, where conventional schemes perform better.
Explore related topics